Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Diffusion Pharmaceuticals Inc. | dffn20170331ex322.htm |
| EX-31.2 - EXHIBIT 31.2 - Diffusion Pharmaceuticals Inc. | dffn20170331ex312.htm |
| EX-31.1 - EXHIBIT 31.1 - Diffusion Pharmaceuticals Inc. | dffn20170331ex311.htm |
| EX-10.4 - EXHIBIT 10.4 - Diffusion Pharmaceuticals Inc. | lease1317carltonaveste400fu.htm |
| EX-4.2 - EXHIBIT 4.2 - Diffusion Pharmaceuticals Inc. | dffn20170331ex42registrati.htm |
| 10-Q - 10-Q - Diffusion Pharmaceuticals Inc. | dffn2017033110-q.htm |
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Diffusion Pharmaceuticals Inc. (the “Company”) for the quarter ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David G. Kalergis, Chairman and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. | |
/s/ David G. Kalergis | |
David G. Kalergis | |
Chairman and Chief Executive Officer | |
May 15, 2017 | |